Associated Papers
High-Frequency Mutations in TP53, AXIN1, CTNNB1, and KRAS, and Polymorphisms in JAK1 Genes Among Mongolian HCC Patients.
Bold N et al.
Cancer Reports (hoboken, N.j.), 2025
Whole-exome sequencing reveals genomic landscape of intrahepatic cholangiocarcinoma and identifies SAV1 as a potential driver.
Zhou ZJ et al.
Nature Communications, 2024
39551842 (PubMed )
Supplement: 41467_2024_54387_MOESM3_ESM.xlsx › Supplementary_Data_2
Study of sex-biased differences in genomic profiles in East Asian hepatocellular carcinoma.
Huang CY et al.
Discover Oncology, 2024
Deep whole-genome analysis of 494 hepatocellular carcinomas.
Chen L et al.
Nature, 2024
Somatic Evolution in Non-neoplastic IBD-Affected Colon.
Olafsson S et al.
Cell, 2020
32697969 (PubMed )
Supplement: mmc4.xlsx › A__TCGA_hotspots
The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
Lu ZN et al.
Hepatology (baltimore, Md.), 2020
Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.
Tang J et al.
Theranostics, 2020
32373219 (PubMed )
Supplement: thnov10p5384s2.xlsx › S5-All_HCC_Mutations
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.
Alonso-Peña M et al.
Cancer Drug Resistance (alhambra, Calif.), 2019
Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.
Yang S et al.
Oncotarget, 2016
Diverse modes of genomic alteration in hepatocellular carcinoma.
Jhunjhunwala S et al.
Genome Biology, 2014
25159915 (PubMed )
Supplement: 13059_2014_436_MOESM1_ESM.xlsx › Table_S2
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.
Kan Z et al.
Genome Research, 2013
Liver cancer oncogenomics: opportunities and dilemmas for clinical applications.
Marquardt JU et al.
Hepatic Oncology, 0
Select a paper to view details